Affordable Access

Access to the full text

Phenolisation of the Sinus Tract in Recurrent Sacrococcygeal Pilonidal Sinus Disease: A Prospective Cohort Study

Authors
  • Pronk, Akke1
  • Vissink, Michiel1
  • Smakman, Niels1
  • Furnee, Edgar2
  • 1 Surgery, Diakonessenhuis, Utrecht, NLD
  • 2 Surgery, University Medical Center Groningen, Groningen, NLD
Type
Published Article
Journal
Cureus
Publisher
Cureus, Inc.
Publication Date
May 15, 2020
Volume
12
Issue
5
Identifiers
DOI: 10.7759/cureus.8129
PMID: 32550049
PMCID: PMC7294870
Source
PubMed Central
Keywords
License
Green
External links

Abstract

Purpose Phenolisation is a minimally invasive treatment option in patients with primary pilonidal disease. However, most studies focus on patients with primary pilonidal sinus disease, while data of patients with recurrent pilonidal disease are very scarce. The purpose of this study was to evaluate phenolisation of the sinus tract in patients with recurrent pilonidal sinus disease after previous surgery for SPSD. Methods This single-center prospective cohort study included 60 patients with recurrent pilonidal disease. Loss of days of normal daily activities, surgical site infection, wound epithelization, quality of life, and complaints related to pilonidal disease were postoperatively assessed. Results A total of 57 patients (95%) were treated with phenolisation and the median loss of days of normal daily activities was 5.0 (1.0 - 12.0) days. Fifty-one patients (89.5%) resumed normal daily activities after two weeks. Surgical site infection occurred in five patients (8.8%). Compared to preoperative scores, quality of life was significantly higher 12 weeks postoperatively (p=0.014) and pain and itch scores were lower after six and 12 weeks (p ≤ 0.005). Wounds were completely healed in 45 of 51 patients (89.8%) who were available after 12 weeks of follow-up. Conclusion Phenolisation for recurrent pilonidal disease is safe with a median complete return to daily activities within five days and complete wound healing after three months in 90%. Therefore, phenolisation should be considered as a treatment option in patients with recurrent pilonidal sinus disease.

Report this publication

Statistics

Seen <100 times